An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 11, Issue 4, 2011, Pages 375-380

  Senna, Gianenrico ^a   Calderon, Moises ^b   Makatsori, Melina ^b   Ridolo, Erminia ^c   Passalacqua, Giovanni ^d  

^a UNIVERSITY OF VERONA   (Italy)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

allergen immunotherapy; markers; surrogate

Indexed keywords

BIOLOGICAL MARKER; CD23 ANTIGEN; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; INTERLEUKIN 10; LEUKOTRIENE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ANTIBODY TITER; ARTICLE; ASTHMA; BASOPHIL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DISEASE MARKER; DOWN REGULATION; DRUG ACTIVITY; EOSINOPHIL; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LANGERHANS CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; MITE; PERENNIAL RHINITIS; POLLEN ALLERGY; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; REPRODUCIBILITY; RESPIRATORY TRACT ALLERGY; SENSITIZATION; SKIN ALLERGY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALLERGENS; BIOLOGICAL MARKERS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHILS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RESPIRATORY HYPERSENSITIVITY; SKIN TESTS; TREATMENT OUTCOME;

EID: 79960847837     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328348a7cd     Document Type: Article

References (66)

1. Durham SR, Leung DY, One hundred years of immunotherapy: time to ring the changes, J Allergy Clin Immunol 2011; 127:3-7.
2. Calderon MA, Casale TB, Togias A, et al, Allergen specific immunotherapy for respiratory diseases: from meta-analysis to registration and beyond, J Allergy Clin Immunol 2011; 127:30-38.
3. Canonica GW, Baena Cagnani CE, Bousquet J, et al, Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy, A statement of a World Allergy Organization (WAO) taskforce, Allergy 2007; 62:317-324.
4. Chon JN, Introduction to surrogate markers, Circulation 2004; 109 (25 Suppl 1):20-21.
5. Loureiro G, Tavares B, Chieira C, Pereira C, Effect of dermatophagoides specific immunotherapy on cutaneous reactivity, Eur Ann Allergy Clin Immunol 2007; 39:5-8.
6. Lima MT, Wilson D, Pitkin L, et al, Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial, Clin Exp Allergy 2002; 32:507-514. (Pubitemid 34429567)
7. Rossi R, Monasterolo G, Passalacqua G, The biological potency of different extracts for sublingual immunotherapy assessed by skin prick test, Eur Ann Allergy Clin Immunol 2010; 42:112-114.
8. Bullens DMA, Monitoring the effect of allergen immunotherapy: a clinician's dream comes true? Clin Exp Allergy 2010; 40:958-961.
9. Dordal MT, Lluch-Bernal F, Sanchez MC, et al, Allergen-specific nasal provocation test: review by the rhinoconjunctivitis committee of the Spanish Society of Allergology and Clinical Immunology, J Invest Allergol Clin Immunol 2011; 21:1-12.
10. Horak F, Zieglermayer P, Zieglermayer R, et al, Early onset of action of 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen chamber, J Allergy Clin Immunol 2009; 124:471-477.
11. Jarolim E, Poulsen LK, Stadler BM, et al, A long-term follow up study of hyposensitization with immunoblotting, J Allergy Clin Immunol 1990; 85:996-1004. (Pubitemid 20212453)
12. Di Lorenzo G, Mansueto P, Pacor ML, et al, Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen specific immunotherapy, J Allergy Clin Immunol 2009; 123:1103-1110.
13. Flicker S, Steinberger P, Norderhaug L, et al, Conversion of grass pollen allergen specific human IgE into protective IgG antibody, Eur J Immunol 2002; 32:2156-2162. (Pubitemid 34965878)
14. Peng ZK, Naclerio RM, Norman PS, Adkinson NF Jr, Quantitative IgE- and IgG- subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol 1992; 89:519-529.
15. Otsuka H, Mezawa A, Ohnishi M, et al, Changes in nasal metachromatic cells during allergen immunotherapy, Clin Exp Allergy 1991; 21:115-119.
16. Gelhar K, Schlaak K, Becker W, Bufe A, Monitoring allergen immunotherapy of pollen allergic patients, The ratio of allergen specific IgG4 to IgG1 correlates with clinical outcome, Clin Exp Allergy 1999; 29:497-506. (Pubitemid 29179819)
17. Mobs C, Slotosh C, Loffler H, et al, Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy. Int Arch Allergy Immunol 2008; 147:171-178.
18. Bodtger U, Ejrnaes AM, Hummelshoj L, et al, Is immunotherapy-induced birch pollen-specific IgG4 marker for decreased allergen-specific sensitivity? Int Arch Allergy Immunol 2005; 136:340-346. (Pubitemid 41094497)
19. Niederberger V, Horak F, Vrtala S, et al, Vaccination with genetically engineered allergens prevents progression of allergic disease, Proc Natl Acad Sci U S A 2004; 101:14677-14682. (Pubitemid 39346742)
20. Wacholz PA, Soni NK, Till SJ, Durham SR, Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass immunotherapy, J Allergy Clin Immunol 2003; 112:915-922. (Pubitemid 37412059)
21. James LK, Shamji MH, Walker SM, et al, Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127:509-516.
22. Liu YH, Tsai JJ, Production of salivary immunoglobulin A and suppression of dermatophagoides pteronyssinus-induced airway inflammation by local nasal immunotherapy, Int Arch Allergy Immunol 2005; 138:161-168.
23. Scadding GW, Shamji MH, Jacobson MR, et al, Sublingual grass pollen immunotherapy is associated with increase in sublingual Foxp3-expressing cells and elevated allergen specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cell, Clin Exp Allergy 2011; 40:598-606.
24. Durham SR, Ying S, Varney VA, et al, Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4 T lymphocytes and eosinophils in the nasal mucosa and increases the number of cell expressing messenger RNA for interferon gamma, J Allergy Clin Immunol 1996; 97:1356-1365.
25. James LK, Durham SR, Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy 2008; 38:1074-1088.
26. Francis JN, Till SJ, Durham SR, Induction of IL10 CD4 CD25 T cells by grass pollen immunotherapy, J Allergy Clin Immunol 2003; 11:1255-1261.
27. Nouri-Aria KT, Wacholz PA, Francis JN, Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity, J Immunol 2004; 172:3252-3259. (Pubitemid 38263717)
28. Cosmi L, Santarlasci V, Angeli R, Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen specific immunoglobulin E and increases both interferon g and interleukin 10 production, Clin Exp Allergy 2006; 36:261-272. (Pubitemid 43344707)
29. Campbell JD, Buckland KF, McMillan SJ, Peptide immunotherapy in allergic asthma generates IL-10 dependent immunological tolerance associated with linked epitope suppression, J Exp Med 2009; 206:1535-1547.
30. Yamanaka K, Yuta A, Kakeda M, Induction of IL-10 producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol 2009; 124:842-857.
31. Piconi S, Trabattoni D, Rainone V, et al, Immunological effect of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed Cell Death Ligand 1, IL-10 and IgG4, J Immunol 2010; 185: 7723-7730.
32. Van Overtvelt L, Wambre E, Maillere B, Assessment of Bet v1-specific CD4 T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers, J Immunol 2008; 180:4514-4522.
33. Akdis CA, Akdis M, Mechanisms and treatment of the allergic disease in the big picture of regulatory T cells, J Allergy Clin Immunol 2009; 123:735-746.
34. Ajduk J, Marinic I, Aberle N, et al, Effect of house dust mite immunotherapy on transforming growth factor beta 1-producing T cells in asthmatic children, Ann Allergy Asthma Immunol 2008; 100:314-322. (Pubitemid 351520321)
35. Pilette C, Nouri-Aria KT, Jacobson MR, et al, Grass pollen immunotherapy induces an allergen specific IgA2 antibody response with mucosal TGF-beta expression, J Immunol 2007; 178:4658-4666. (Pubitemid 46492419)
36. O'Hehir RE, Gardner LM, de Leon MM, et al, House dust mite sublingual immunotherapy: the role of transforming growth factor beta and functional regulatory T cell, Am Resp Crit Care Med 2009; 180:936-944.
37. Ciprandi G, De Amici M, Negrini S, et al, TGF-b and IL-17 serum levels and specific immunotherapy, Int Immunopharmacol 2009; 9:1247-1249.
38. Ciprandi G, De Amici M, Tosca M, Marseglia G, Serum Transforming Growth Factor beta levels depend on allergen exposure in allergic rhinitis, Int Arch Allergy Immunol 2010; 152:66-70.
39. Ohno I, Nitta Y, Yamauchi K, et al, Transforming growth factor beta 1 (TGF-b1) gene expression by eosinophils in asthmatic airway inflammation, Am J Respir Cell Mol Biol 1996; 15:404-409. (Pubitemid 126439908)
40. Nelson HS, Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007; 119:872-880. (Pubitemid 46527809)
41. Marogna M, Spadolini I, Massolo A, et al, Long lasting effect of sublingual immunotherapy according to its duration: a 15 years prospective, J Allergy Clin Immunol 2010; 126:969-975.
42. Kim ST, Han DH, Moon IJ, et al, Clinical and immunologic effects of sublingual immunotherapy on patients with allergic rhinitis to house dust mite: 1 year follow up results, Am J Rhinol Allergy 2010; 24:271-275.
43. Klimek L, Wolf H, Mewes T, Dorman D, et al, The effect of short term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions, J Allergy Clin Immunol 1999; 103:47-53. (Pubitemid 29063190)
44. Pronk-Admiraal CJ, Schilte PP, Bartles PC, Effect of immunotherapy on eosinophil activation in pollen sensitive children, Clin Lab 2001; 4:231-238. (Pubitemid 32492870)
45. Kopp MV, Mayatepek E, Engels E, et al, Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti IgE (omalizumab), Pediatr Allergy Immunol 2003; 14:401-404. (Pubitemid 37376974)
46. Dinakar C, Van Osdol TJ, Barnes CS, et al, Changes in exhaled nitric oxide levels with immunotherapy, Allergy Asthma Proc 2006; 27:140-144. (Pubitemid 43700865)
47. Passalacqua G, Albano M, Fregonese L, et al, Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis, Lancet 1998; 351:629-632. (Pubitemid 28098445)
48. Passalacqua G, Senna G, Dama AR, et al, The relationship between clinical efficacy of immunotherapy and serum intercellular adhesion molecule 1 levels. J Invest Allergol Clin Immunol 1998; 18:123-124. (Pubitemid 28239243)
49. Baiardini I, Bousquet PJ, Brzoza Z, et al, Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper, Allergy 2010; 65:290-295.
50. Canonica GW, Baena Cagnani C, Bousquet J, et al, Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy, A statement of a World Allergy Organization (WAO) taskforce, Allergy 2007; 62:317-324.
51. Bousquet J, Scheinmann P, Guinnepain MT, et al, Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study, Allergy 1999; 54:249-260.
52. Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martin-Garcia C, et al, Immunotherapy with a depigmented glutaraldehyde polymerized extract: changes in quality of life, Clin Exp Allergy 2005; 35:572-578. (Pubitemid 40769279)
53. Frew AJ, Powell RJ, Corrigan CJ, Durham SR, UK Immunotherapy Study Group, Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis, J Allergy Clin Immunol 2006; 117:319-325. (Pubitemid 43190146)
54. Passalacqua G, Pasquali M, Ariano R, et al, Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites, Allergy 2006; 61:849-854. (Pubitemid 43893986)
55. Durham SR, Yang WH, Pedersen MR, et al, Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis, J Allergy Clin Immunol 2006; 117:802-809.
56. Moreno-Ancillo A, Moreno C, Ojeda P, et al, Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing, J Investig Allergol Clin Immunol 2007; 17:399-405. (Pubitemid 350232565)
57. Powell RJ, Frew AJ, Corrigan CJ, Durham SR, Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007; 62:1335-1338. (Pubitemid 47537501)
58. Didier A, Malling HJ, Worm M, et al, Optimal dose, efficacy, and safety of oncedaily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis, J Allergy Clin Immunol 2007; 120:1338-1345. (Pubitemid 350225683)
59. Lizaso MT, Tabar AI, García BE, et al, Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety, Pediatr Allergy Immunol 2008; 19:76-81.
60. Colás C, Monzó n S, Venturini M, Lezaun A, Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule, J Allergy Clin Immunol 2006; 117:810-816. (Pubitemid 44313815)
61. Pham-Thi N, Scheinmann P, Fadel R, et al, Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures, Pediatr Allergy Immunol 2007; 18:47-57. (Pubitemid 46232283)
62. Roder E, Berger MY, Hop WC, et al, Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care, J Allergy Clin Immunol 2007; 119:892-898. (Pubitemid 46527818)
63. de Blay F, Barnig C, Kanny G, et al., SUBLIM Group, sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study, Ann Allergy Asthma Immunol 2007; 99:453-461. (Pubitemid 350086205)
64. Dahl R, Kapp A, Colombo G, et al, Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-440. (Pubitemid 44160721)
65. Wacholz PA, Durham SR, Mechanisms of immunotherapy: IgG revisited, Curr Opin Allergy Clin Immunol 2004; 4:313-318. (Pubitemid 39006847)
66. Ciprandi G, Alesina R, Ariano R, et al, Characteristics of patients with allergic polysensitization: the POLISMAIL study, Eur Ann Allergy Clin Immunol 2008; 40:77-83.